Commercial CVS obesity drug deal puts Lilly on equal footing with Novo BioPharma DiveThe agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.Metabolic & GLP-1Read full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioPharma Dive The agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK hails ‘unprecedented’ cure rates with hep B drug Related Stories Commercial Kardigan targets IPO to support cardiology pipeline progression pharminent May 27, 2026 Commercial Lilly UK recruits ex-England cricketer as obesity champion pharminent May 15, 2026 Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment pharminent May 12, 2026
